Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393821 · ClinicalTrials.gov registry record · NA
Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01393821: Completed NA study, sponsored by Mayo Clinic.
NCT01393821 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01393821, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab
Interventions
- OTHER placebo
- OTHER questionnaire administration
- PROCEDURE management of therapy complications
- DRUG menadione topical lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-01-23 |
| Est. Completion | 2018-07-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393821
The ClinicalTrials.gov registry entry for NCT01393821 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01393821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01393821 about?
NCT01393821 is a clinical study titled "Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab". This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distre...
What is the current status of trial NCT01393821?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2012-01-23. Estimated completion is 2018-07-14.
What interventions are being tested in trial NCT01393821?
The interventions under investigation include: placebo (OTHER), questionnaire administration (OTHER), management of therapy complications (PROCEDURE), menadione topical lotion (DRUG).
Who is sponsoring clinical trial NCT01393821?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.